VALEO PHARMA INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.105 CAD | -4.55% |
|
-30.00% | -41.67% |
| Mar. 22 | Valeo Pharma Inc. Announces Appointment of Al Moghaddam to Board of Directors | CI |
| Mar. 15 | Transcript : Valeo Pharma Inc., Q1 2024 Earnings Call, Mar 15, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Valeo Pharma Inc. is a Canadian pharmaceutical company. The Company acquires, or in-licenses branded pharmaceuticals and hospital specialty products for sale in Canada. The Company is engaged in the commercialization of prescription products in Canada with a focus on respiratory/allergy, ophthalmology and hospital specialty products. Its respiratory/allergy products include Enerzair Breezhaler, Atectura Breezhaler and Allerject. The ophthalmology products include Xiidra and Simbrinza. Its specialty products include Redesca, Onstryv, M-Eslon, Yondelis and Ametop Gel 4%. The Company's wholly owned subsidiary is VPI Pharmaceuticals Inc.
Sector
Pharmaceuticals
Calendar
2024-04-25
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.105
CAD
Average target price
0.5
CAD
Spread / Average Target
+376.19%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -41.67% | 7.58M | |
| +27.92% | 672B | |
| +26.94% | 570B | |
| -4.59% | 360B | |
| +16.38% | 321B | |
| +9.39% | 300B | |
| +7.26% | 217B | |
| +5.75% | 199B | |
| -8.59% | 204B | |
| -8.58% | 149B |
- Stock Market
- Equities
- VPH Stock
- News Valeo Pharma Inc.
- Valeo Pharma Brief: Reporting Record quarterly revenues of $12.7 million in Q4-22, up 274% over Q4-21
